
Blogs & Insights
Explore the latest in biotech and research, crafted to inspire your next breakthrough.
New Updates

PepGen's DM1 Data: Splicing Correction and the Preclinical Questions Ahead
View Details

AMT-130 and HTT-Lowering Therapies: Lessons from Preclinical Huntington's Disease Models
View Details

iPSCs in Drug Development: Disease Modeling and Screening
View Details

siRNA Goes Public Again: CITY vs Alnylam and the In Vivo Models Behind the Next Wave
View Details
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Filter By
All Topics
Animal Science and Quality
Autoimmunity & Inflammation
Cardiovascular Research
Cell & Gene Therapy
Genetic Disorders and Genomics
HUGO-Ab
Immunology
Infectious Diseases & Vaccines
Metabolism & Obesity
Neuroscience
Oncology
Ophthalmology
Precision Medicine & Biomarkers
Rare Diseases
Regenerative Biology
Milestones & Highlights
Filter By

Neuroscience
PepGen's DM1 Data: Splicing Correction and the Preclinical Questions Ahead
View Details

Neuroscience
AMT-130 and HTT-Lowering Therapies: Lessons from Preclinical Huntington's Disease Models
View Details

Cell & Gene Therapy
iPSCs in Drug Development: Disease Modeling and Screening
View Details

Animal Science and Quality
siRNA Goes Public Again: CITY vs Alnylam and the In Vivo Models Behind the Next Wave
View Details

HUGO-Ab
AI Antibody Discovery: From Designed Binders to Validated Drug Candidates
View Details

Metabolism & Obesity
ALK7 Obesity Target: What Roche's $1.16B Rona RNAi Deal Means for Fat-Focused Drug Discovery
View Details

Ophthalmology
More Opsin, or a Different Target? The Delivery Question Behind This Year's Optogenetics Nobel
View Details

HUGO-Ab
Bispecific ADCs: Solving Antigen Heterogeneity or Masking Payload Resistance?
View Details

Metabolism & Obesity
Dual-Target siRNA: the Future of RNAi Therapeutics
View Details
1
2
3
4
5
6
...
21
22
More



